HC Wainwright Lifts Earnings Estimates for PDS Biotechnology

PDS Biotechnology Corporation (NASDAQ:PDSB) – Analysts at HC Wainwright raised their Q3 2025 earnings per share (EPS) estimates for shares of PDS Biotechnology in a note issued to investors on Wednesday, August 13th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of ($0.25) per share for the quarter, up from their prior estimate of ($0.26). HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for PDS Biotechnology’s current full-year earnings is ($1.20) per share. HC Wainwright also issued estimates for PDS Biotechnology’s FY2025 earnings at ($0.96) EPS, FY2026 earnings at ($0.90) EPS, FY2027 earnings at ($1.01) EPS and FY2028 earnings at ($0.83) EPS.

PDS Biotechnology (NASDAQ:PDSB) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.03.

Separately, Wall Street Zen lowered shares of PDS Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, June 14th.

PDS Biotechnology Price Performance

NASDAQ PDSB opened at $1.19 on Friday. PDS Biotechnology has a 52 week low of $0.85 and a 52 week high of $4.29. The firm has a market capitalization of $55.49 million, a P/E ratio of -1.29 and a beta of 0.95. The company has a quick ratio of 2.33, a current ratio of 2.92 and a debt-to-equity ratio of 0.81. The company has a 50-day moving average price of $1.32 and a 200-day moving average price of $1.32.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Two Sigma Investments LP grew its stake in shares of PDS Biotechnology by 273.5% during the 4th quarter. Two Sigma Investments LP now owns 65,732 shares of the company’s stock valued at $107,000 after acquiring an additional 48,132 shares during the period. Jane Street Group LLC bought a new position in shares of PDS Biotechnology during the 4th quarter valued at approximately $58,000. Raymond James Financial Inc. bought a new position in shares of PDS Biotechnology during the 4th quarter valued at approximately $26,000. Blair William & Co. IL grew its stake in shares of PDS Biotechnology by 63.3% during the 1st quarter. Blair William & Co. IL now owns 257,200 shares of the company’s stock valued at $306,000 after acquiring an additional 99,700 shares during the period. Finally, Renaissance Technologies LLC grew its stake in shares of PDS Biotechnology by 331.0% during the 4th quarter. Renaissance Technologies LLC now owns 100,000 shares of the company’s stock valued at $163,000 after acquiring an additional 76,800 shares during the period. 26.84% of the stock is currently owned by institutional investors.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.